Market Research Report
Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||358700|
|Published||Content info||76 Pages
Delivery time: 1-2 business days
|Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019|
|Published: December 27, 2019||Content info: 76 Pages||
Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 2, 4, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules respectively.
Report covers products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Ophthalmology, Genito Urinary System And Sex Hormones, Male Health, Central Nervous System, Musculoskeletal Disorders, Oncology, Respiratory and Women's Health which include indications Glaucoma, Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Kidney Fibrosis, Arthritis, Chemotherapy Induced Pain, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Erectile Dysfunction, Female Sexual Dysfunction, Hepatocellular Carcinoma, Inflammation, Male Sexual Dysfunction, Melanoma, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.